Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2024-05-14
2024-09-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Composition and Bacterial Diversity of the Vaginal Microbiota in Healthy Versus Pathological Conditions (Bacterial Vaginosis) Using a Targeted Metagenomic Approach (RNA 16s)
NCT04989543
Research on Vaginal Microbiota Evaluation Unified Standards Based on Gram Staining
NCT05997160
Examining the Impact of Tampon Use on the Vaginal Microbiota
NCT03346759
Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples.
NCT03680898
A Pilot Study To Assess The Impact Of A Camstent Coated Catheter On Clinical Bacteriuria
NCT04658719
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible participants will be enrolled in the study for a total duration of 1 day, where they will provide consent, answer a questionnaire and collect the vaginal samples.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
I2. BMI between 18 and 30 kg/m² (limits included),
I3. Good general and mental health within the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination,
I4. Able and willing to participate to the study by complying with the protocol procedures as evidenced by the dated and signed informed consent form,
I5. Affiliated with a social security scheme,
I6. Women who have had a vaginal or urinary infection in the last two years.
Exclusion Criteria
E2. Any infectious gastrointestinal complaint within 4 weeks before V1
E3. Suffering from a metabolic disorder such as diabetes, thyroidal trouble, arterial hypertension or other metabolic disorder or any disease requiring a chronic treatment
E4. Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, cardiac, hepatic or biliary disorders ongoing, chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble, etc.) or disease found to be inconsistent with the conduct of the study by the investigator
E5. Suffering from a pathology of the oral sphere (untreated caries, gingivitis, periodontitis, abscess, etc.) or having a positive result in an oral swab test for STIs (chlamydia, gonococcus, syphilis, herpes, etc.)
E6. Women affected by a Sexually Transmitted Infection (STI) or Disease (STD) such as HPV (Human PapillomaVirus), Chlamydia infection, syphilis, gonorrhea, genital herpes
E7. Having undergone a surgical procedure likely to disrupt the gut microbiome within the 6 months prior to the V1 visit, especially bariatric surgery
E8. Coloscopy within 3 months prior to the visit
E9. Women who gave birth within one year of the visit, women who are pregnant or intend to become pregnant during the study, women who are breastfeeding
E10.Previous or current antibiotic, antiviral, antifungal, proton pump inhibitor, or any treatment which may disrupt the microbiota in the 4 weeks prior to the V1 visit
E11.In the process of quitting smoking or having started smoking less than 6 months ago
E12.Taking part in another clinical trial or being in the exclusion period of a previous clinical trial
E13. Having received, during the last 12 months, indemnities for clinical trial higher or equal to 6000 Euros
E14.Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision
E15.Presenting a psychological or linguistic incapability to sign the informed consent
E16.Impossible to contact in case of emergency
18 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioFortis
OTHER
Lallemand Health Solutions
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isabelle Metreau, MD
Role: PRINCIPAL_INVESTIGATOR
Biofortis, Unité d'Investigation Clinique de Saint-Herblain
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biofortis, Unité d'Investigation Clinique
Paris, , France
Biofortis, Unité d'Investigation Clinique
Saint-Herblain, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A01997-36
Identifier Type: OTHER
Identifier Source: secondary_id
L-031
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.